Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON JUNE 4, 2026

The Board is pleased to announce that all the resolutions proposed as set out in the notice of 2025 Annual General Meeting (the "**AGM**") were duly passed by the Shareholders by way of poll at the AGM.

References are made to the notice of the AGM and the circular (the "**Circular**") of Suzhou Basecare Medical Corporation Limited (the "**Company**") dated May 12, 2026. Capitalised terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

POLL RESULTS OF THE AGM

The AGM was chaired by Dr. Liang Bo, the chairman and general manager, and was successfully held at No. 77 Jingu Road, Suzhou Industrial Park, Suzhou, Jiangsu Province, PRC on Thursday, June 4, 2026. The AGM was convened in accordance with the requirements of the relevant laws and regulations of the PRC and the articles of association of the Company, and the poll results are lawful and valid.

The Board is pleased to announce that all the resolutions proposed as set out in the notice of the AGM were duly passed by the Shareholders by way of poll at the AGM.

The poll results in respect of all the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		NO. OF SHARES VOTED (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the report of the board (the "**Board**") of directors of the Company for 2025.	194,562,929 (99.3007%)	1,370,090 (0.6993%)	0 (0.0000%)
2.	To consider and approve the report of the board of supervisors of the Company for 2025.	194,562,929 (99.3007%)	1,370,090 (0.6993%)	0 (0.0000%)
3.	To consider and approve the annual report of the Company and its subsidiaries (together, the "**Group**") for 2025.	194,562,929 (99.3007%)	1,370,090 (0.6993%)	0 (0.0000%)
4.	To consider and approve the financial accounts report of the Group for 2025.	179,373,757 (91.5485%)	1,370,090 (0.6993%)	15,189,172 (7.7522%)
5.	To consider and approve the financial budget of the Group for 2026.	179,373,757 (91.5485%)	1,370,090 (0.6993%)	15,189,172 (7.7522%)
6.	To consider and approve the annual profit distribution plan of the Company for 2025.	194,562,929 (99.3007%)	1,370,090 (0.6993%)	0 (0.0000%)
7.	To consider and approve the re-appointment of KPMG to be the auditor of the Company for 2026 with a term of one year, and authorize the Board to determine the specific matters, including but not limited to their remunerations, in relation to such appointment.	194,562,929 (99.3007%)	1,370,090 (0.6993%)	0 (0.0000%)
8.	To consider and approve the proposed remuneration plan for Directors.	179,373,757 (91.5485%)	1,370,090 (0.6993%)	15,189,172 (7.7522%)

As more than one-half of the votes were cast in favour of each of the proposed resolutions numbered 1 to 8 above, the proposed resolutions numbered 1 to 8 proposed at the AGM were duly passed as ordinary resolutions of the Company.

SPECIAL RESOLUTIONS		NO. OF SHARES VOTED (%)		
		FOR	AGAINST	ABSTAIN
9.	To consider and approve the resolution on the grant of a General Mandate to the Board to issue additional Shares.	192,347,021 (98.1698%)	3,585,998 (1.8302%)	0 (0.0000%)
10.	To consider and approve the resolution on the grant of a General Mandate to the Board to repurchase H Shares.	179,373,757 (91.5485%)	1,370,090 (0.6993%)	15,189,172 (7.7522%)
11.	To consider and approve the proposed amendments to the articles of association of the Company.	194,562,929 (99.3007%)	1,370,090 (0.6993%)	0 (0.0000%)

As more than two-thirds of the votes were cast in favour of the proposed resolutions numbered 9 to 11 above, the proposed resolutions numbered 9 to 11 proposed at the AGM were duly passed as special resolutions of the Company.

Notes:

1. As at the date of the AGM, the total number of issued ordinary Shares was 273,526,000 Shares (including 82,713,835 H Shares, 183,181,817 Domestic Shares and 7,630,348 Unlisted Foreign Shares), which represented the total number of Shares entitling the Shareholders to attend and vote on the proposed resolutions at the AGM.

2. For the avoidance of doubt, holders of treasury shares, if any, are required to abstain from voting at the AGM. As at the date of the AGM, the Company did not hold any treasury shares (including any treasury shares held or deposited with CCASS), and no repurchased shares which are pending cancellation and should be excluded from the total number of issued Shares for the purpose of the AGM. The Company confirms that it did not exercise its voting rights in respect of the treasury shares at the AGM.

3. There were no Shareholders, who, pursuant to Rule 13.40 of the Listing Rules, were required to abstain from voting in favour of any of the proposed resolutions at the AGM, nor were there any Shareholders who were required under the Listing Rules to abstain from voting.

4. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

5. The total number of Shares held by the Shareholders or their proxies who have attended the AGM and are entitled to vote is 195,933,019 Shares, representing approximately 71.63% of the total number of issued Shares as at the date of the AGM.

6. The Company's H shares registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

7. All Directors attended the AGM.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, June 4, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.